Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 2/8/2015 |
| Start Date: | September 2008 |
| End Date: | September 2014 |
| Contact: | Teresa Lopez-Castro, Ph.D. |
| Email: | lopezcastro.phd.ccny@gmail.com |
| Phone: | 212-650-8355 |
A Randomized Trial of Concurrent Treatment for PTSD and Substance Dependence
This treatment intervention trial is designed for men and women with substance dependence
and comorbid Post-Traumatic Stress Disorder (PTSD). Participants will be randomly assigned
to one of three conditions (two behavioral treatments [Concurrent Treatment of PTSD and
Substance Dependence and Relapse Prevention Therapy] and a delayed treatment control group)
and will be evaluated at baseline and four follow-up points (post-treatment, 1-month, 2-
month and 3-month post-treatment).
and comorbid Post-Traumatic Stress Disorder (PTSD). Participants will be randomly assigned
to one of three conditions (two behavioral treatments [Concurrent Treatment of PTSD and
Substance Dependence and Relapse Prevention Therapy] and a delayed treatment control group)
and will be evaluated at baseline and four follow-up points (post-treatment, 1-month, 2-
month and 3-month post-treatment).
This study will enhance the knowledge and understanding of concurrently treating individuals
with substance use disorders and PTSD in hopes of facilitating treatment retention and
increasing the likelihood for more positive treatment outcomes. Following NIDA's stage model
for behavior therapies development, this study will take the next step building upon
promising findings from Stage IA work with an exposure-based therapy modified to use safely
with substance dependent individuals.
This study is a randomized clinical trial to assess the relative efficacy of two active
treatment conditions versus a delayed treatment control group for substance dependent
individuals who also meet criteria for current PTSD according to the diagnostic standards
set by the DSM-IV. Eligible participants will be randomly assigned to either: (1) Concurrent
Treatment of PTSD and Substance Dependence (CTPSD); (2) Relapse Prevention Treatment (RPT)
or a (3) Delayed Treatment Control Group (DTCG). The study is a three armed randomized
controlled trial with repeated outcome measures at post treatment and 1-,2-, and 3-months
post-treatment follow-up points.
with substance use disorders and PTSD in hopes of facilitating treatment retention and
increasing the likelihood for more positive treatment outcomes. Following NIDA's stage model
for behavior therapies development, this study will take the next step building upon
promising findings from Stage IA work with an exposure-based therapy modified to use safely
with substance dependent individuals.
This study is a randomized clinical trial to assess the relative efficacy of two active
treatment conditions versus a delayed treatment control group for substance dependent
individuals who also meet criteria for current PTSD according to the diagnostic standards
set by the DSM-IV. Eligible participants will be randomly assigned to either: (1) Concurrent
Treatment of PTSD and Substance Dependence (CTPSD); (2) Relapse Prevention Treatment (RPT)
or a (3) Delayed Treatment Control Group (DTCG). The study is a three armed randomized
controlled trial with repeated outcome measures at post treatment and 1-,2-, and 3-months
post-treatment follow-up points.
Inclusion Criteria:
1. Men and women who are a minimum of 18 years and maximum of 65 years.
2. Participants meet DSM-IV criteria for current or past substance dependence
3. Participants must have used alcohol or other drugs within the past 3 months
4. Participants must speak English
5. Participants must meet DSM-IV criteria for current PTSD in response to on an
interpersonal, civilian trauma
6. Participants are capable of giving informed consent and capable of complying with
study procedures.
7. Participants demonstrate no gross organic mental syndrome
Exclusion Criteria:
1. Participants who are currently suicidal or homicidal
2. Participants who carry a diagnosis of BiPolar I or psychotic disorders are
exclusionary.
3. Participants receiving PTSD-specific treatment
4. Participants on anxiolytic, antidepressant or mood stabilizing medications which have
been initiated during the 8 weeks prior to study participation
5. Participants refusing to be audio or video taped
We found this trial at
1
site
Click here to add this to my saved trials
